X0206 3 2021-01-01 0 0001755237 Cyclerion Therapeutics, Inc. CYCN 0001839046 Gault Cheryl C/O CYCLERION THERAPEUTICS, INC. 245 FIRST STREET, 18TH FLOOR CAMBRIDGE MA 02142 true Chief Operating Officer Common Stock 8500 D Common Stock 794 D Employee Stock Option (Right to Buy) 14.4 2023-02-01 Common Stock 526 D Employee Stock Option (Right to Buy) 11.95 2023-12-16 Common Stock 257 D Employee Stock Option (Right to Buy) 15.54 2024-03-03 Common Stock 1379 D Employee Stock Option (Right to Buy) 14.87 2024-11-03 Common Stock 1999 D Employee Stock Option (Right to Buy) 17.2 2025-03-16 Common Stock 975 D Employee Stock Option (Right to Buy) 11.61 2025-08-03 Common Stock 1254 D Employee Stock Option (Right to Buy) 12.11 2025-12-15 Common Stock 8804 D Employee Stock Option (Right to Buy) 11.28 2026-03-01 Common Stock 5533 D Employee Stock Option (Right to Buy) 17.33 2026-12-16 Common Stock 9526 D Employee Stock Option (Right to Buy) 18.47 2027-02-27 Common Stock 13609 D Employee Stock Option (Right to Buy) 19.04 2027-03-01 Common Stock 6742 D Employee Stock Option (Right to Buy) 17.31 2027-12-15 Common Stock 3001 D Employee Stock Option (Right to Buy) 16.02 2028-02-21 Common Stock 27863 D Employee Stock Option (Right to Buy) 14.21 2029-01-29 Common Stock 30273 D Employee Stock Option (Right to Buy) 10.1 2029-09-06 Common Stock 10937 D Employee Stock Option (Right to Buy) 2.48 2030-11-04 Common Stock 1562 D Employee Stock Option (Right to Buy) 19.04 2027-03-01 Common Stock 568 D Employee Stock Option (Right to Buy) 17.31 2027-12-15 Common Stock 1588 D Employee Stock Option (Right to Buy) 16.02 2028-02-21 Common Stock 14760 D Employee Stock Option (Right to Buy) 14.21 2029-01-29 Common Stock 34063 D Employee Stock Option (Right to Buy) 10.1 2029-09-06 Common Stock 24063 D Employee Stock Option (Right to Buy) 2.01 2029-11-22 Common Stock 75000 D Employee Stock Option (Right to Buy) 2.48 2030-11-04 Common Stock 73438 D Includes 7,204 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan. Consists of shares underlying unvested restricted stock units ("RSUs"), each representing the right to receive one share of Common Stock, granted on April 1, 2019, and received as a result of the equitable adjustment of outstanding RSUs held prior to the spin-off of the Issuer from its predecessor, effective April 1, 2019 (the "Separation") that will vest on November 18, 2021. These stock options are fully exercisable and were granted by the Issuer's predecessor and were equitably adjusted into stock options of the Issuer pursuant to the Separation. These stock options were issued under the Issuer's 2019 Equity Incentive Plan and are fully exercisable. These stock options vest and become exercisable ratably on the thirteenth day of each month until and including February 13, 2021. These stock options vest and become exercisable ratably on the fifteenth day of each month until and including December 15, 2021. These stock options vest and become exercisable ratably on the first day of each month until and including January 1, 2022 These stock options vest and become exercisable ratably on the first day of each month until and including January 1, 2023. These stock options vest and become exercisable ratably on the sixth day of each month until and including September 6, 2023. These stock options vest and become exercisable upon the attainment of both performance-based and service-based hurdles, as follows: (i) 20% of the shares subject to the option, if the average closing price of the common stock reported by Nasdaq for any thirty (30) consecutive trading days equals or exceeds $10; plus an additional (ii) 40% of the shares, if the average closing price equals or exceeds $20; plus an additional (iii) 40% of the shares, if the average closing price equals or exceeds $30; in each case, subject to the continuous employment or service through the later of the date that the performance hurdles set forth above are attained (but no later than December 31, 2024) and December 31, 2021. To the extent unvested as of December 31, 2024, all of these performance-based options will be cancelled. These stock options vest and becomes exercisable ratably on the fourth day of each month until and including November 4, 2024. Exhibit 24 - Power of Attorney By: /s/ Cheryl Gault 2021-01-11